Abstract. Upregulated expression of the CXC chemokine receptor type 7 (CXCR7) promotes breast, lung and prostate cancer progression and metastasis. However, the role of CXCR7 in colon cancer has not been determined. We hypothesized that increased CXCR7 expression may contribute to human colon cancer occurrence and progression. Reverse transcription quantitative polymerase chain reaction and western blot analysis were performed on 34 malignant and 18 normal colon tissue specimens. The specimens were obtained from 19 male and 15 female patients, with a mean age of 52 years (range, 34-79 years). Of the 34 patients, 20 had lymph node metastases. None of the patients had received adjuvant radiotherapy or chemotherapy prior to surgery. This study demonstrated that CXCR7 levels were significantly higher in colon tumors compared with those in normal colon tissue (P﹤0.01). In addition, lymph node metastatic colon tumors exhibited significantly higher CXCR7 expression compared with non-metastatic tumors (P﹤0.01); however, there were no differences in CXCR7 expression among distinct histopathological types (well-differentiated vs. moderately-to-poorly differentiated adenocarcinoma, P﹥0.01). Therefore, the evidence obtained from the present study supports involvement of the upregulated CXCR7 expression in colon tumorigenesis and lymph node metastasis.
Introduction
Several chemokine receptors have been implicated in tumorigenesis and metastasis of various tumors (1) . CXC chemokine ligand 12 (CXCL12), also known as stromal cell-derived factor-1 (SDF-1), plays an important role in progression and organ-specific metastasis of several carcinomas (2) , partly through stimulation of the G protein-coupled receptor, CXCR4. However, CXCR4 inhibition only partially inhibits tumor progression in vivo, suggesting that other factors contribute to epithelial cancer progression (3) .
CXCR7, formerly known as orphan receptor RDC1, was recently identified as a second CXCL12/SDF-1 receptor. Specifically, high-affinity CXCR7-CXCL12/SDF-1 interactions activate chemotaxis in CXCR7-expressing tumor cells and promote tumor growth and metastasis in animal models (1, 2) . Moreover, increased CXCR7 expression directly correlates with greater tumor aggressiveness (3) . Recent studies support a mechanistic role for CXCR7 in several malignancies, including lung cancer (1, 4) , prostate cancer (3), malignant pheochromocytomas (5), papillary thyroid carcinoma (6) , ovarian cancer (7), hepatocellular carcinoma (8) , breast cancer (9) and Kaposi's sarcoma (10) . However, hardly any previous reports have definitively linked CXCR7 upregulation with human colon cancer and related lymph node metastasis and histopathology.
To the best of our knowledge, this study is the first to investigate the association of CXCR7 mRNA and protein upregulation with colon cancer using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, and determine CXCR7 expression in relation to lymph node metastasis.
Patients and methods
Patients. Tissue samples from 34 human colon tumors and 18 normal colon tissue specimens were obtained from 34 patients with primary colon cancer. The patient cohort comprised 19 male and 15 female patients, with a mean age of 52 years (range, 34-79 years). None of the patients had received adjuvant radiotherapy or chemotherapy prior to surgery. Patients with rectal primary tumors were excluded.
The tumor specimens were dissected from resected colon cancer tissues and the normal colon specimens were obtained from the distal resected colon margin. All the resected primary tumors and lymph nodes were histologically examined with hematoxylin and eosin staining. Of the 34 colon cancer patients, 20 were diagnosed with lymph node metastasis. Histologically, 24 patients had well-differentiated adenocarcinomas and 10 had moderately-to-poorly differenti- RT-qPCR analysis. Total RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA was treated with RQ1 RNase-Free DNase (Promega Corporation, Madison, WI, USA). The RT reaction was performed using the RevertAid TM RT kit (Fermentas Life Technologies, Carlsbad, CA, USA) with 1 µl RNA template, 1 µl oligo(dT) primer (0.5 µg/µl), 4 µl X5 reaction buffer, 1 µl R Nase in hibitor, 2 µl dNTPs (10 mM) and 1 µl reverse transcriptase. The reaction mixture (20 µl) was incubated at 42˚C for 60 min, then at 70˚C for 10 min, followed by cooling on ice. RT-qPCR was performed on the resulting cDNA, using the manufacturer's protocol (Takara Bio Inc., Shiga, Japan), in 25 µl reaction volume per capillary. The gene-specific primer sequences ( I nvit rogen) were as fol lows: CXCR7 for wa rd, 5'-CCGTTCCCTTCTCCATTATCGCTGTCTTCT-3' and reverse, 5'-GTGAAGAGGGCGTGCTCCAGCCGGCAG GTGAA-3'; β-actin forward, 5'-GCGAGAAGATGACCC AGATC-3' and reverse, 5'-CCAGTGGTACGGCCAGAGG-3'. The reaction mixture contained 12.5 µl SYBR ® Premix Ex Taq TM II (2x), 2 µl cDNA template, 1 µl primer pair mixture and dH 2 O. RT-qPCR amplification consisted of an initial denaturation step (95˚C for 5 min), 40 cycles of denaturation (94˚C for 20 sec), annealing (53˚C for 20 sec) and extension (72˚C for 20 sec), followed by final incubation at 72˚C for 5 min. All the measurements were normalized to the expression of the 28S ribosomal genes, considered as stable housekeeping genes (β-actin). Gene expression was determined using the ΔΔCt method:
The CXCR7mRNA sequence was obtained from GenBank (accession no. NM_020311).
Western blot analysis. The tissue samples were lysed in ice-cold RIPA buffer (Beyotime Institute of Biotechnology, Shanghai, China). The protein concentrations were determined using bicinchoninic acid (Pierce Biotechnology, Inc., Rockford, IL, USA) from lysates clarified by centrifugation at 12,000 rpm for 20 min. Equivalent protein quantities (30-50 µg) were separated by denaturing SDS-PAGE electrophoresis, transferred to PVDF membranes and blocked in Tris-buffered saline (TBS) containing 5% non-fat dried milk and 0.05% Tween-20. The membranes were incubated overnight with the appropriate primary antibodies (rabbit anti-human CXCR7 antibody and rabbit anti-human GAPDH antibody; both from Abcam, Cambridge, UK) at dilutions specified by the manufacturer, then washed 4 times in TBS/Tween-20 and incubated with horseradish peroxidase-conjugated secondary antibody (goat anti-rabbit IgG HRP conjugate; Dako, Glostrup, Denmark). Blots were then developed using an enhanced chemiluminescence kit (Beyotime). The resulting values were reported as CXCR7/GAPDH densitometric arbitrary units.
Statistical analysis. RT-qPCR data are reported as medians and evaluated statistically using the non-parametric Mann-Whitney test. Western blot analysis data are reported as means ± standard deviations and statistically analyzed using t-tests. The differences were considered statistically significant at P-values of ﹤0.05.
Results
CXCR7 expression is increased in colon cancer. CXCR7 expression was found to be upregulated in human colon cancer and was associated with lymph node metastasis.
The normalized CXCR7 mRNA and protein levels were significantly higher in colon cancer tissues, compared with those in normal colon tissues (Table I, Z=5 .868, P﹤0.001; Figs. 1 and 2, t=4.25, P﹤0.001) . These are the first data demonstrating CXCR7 upregulation in human colon cancer.
Our 34 colon cancer patients were divided into lymph node metastatic (20 patients, positive) and non-metastatic (14 patients, negative) groups. Additionally, the patients were classified histopathologically into 24 cases with well-differentiated and 10 cases with moderately-to-poorly differentiated adenocarcinomas. The CXCR7 mRNA levels were significantly different between the positive and negative lymph node groups (Table I,  Z=3 .92, P﹤0.001). Moreover, CXCR7 mRNA upregulation was positively correlated with lymph node metastasis, namely colon tumors with metastatic lymph nodes exhibited higher CXCR7 levels, whereas non-metastatic tumors exhibited lower CXCR7 expression. No significant difference was found based on histopathological criteria (Table I, Z=1 .096, P=0.273). CXCR7 protein expression was consistent with our CXCR7 mRNA results. The CXCR7 protein level was significantly increased in colon tumors with lymph node metastases compared with the non-metastatic group (Figs. 1 and 2, t=5 .36, P﹤0.001), whereas no significant difference was observed between histopathologically distinct tumor types (Figs. 1 and 2, t=1 .768, P=0.089). Therefore, our results suggest that CXCR7 mRNA and protein upregulation is correlated with lymph node metastasis, but is not associated with the histopathological type.
Discussion
Chemokines are a group of low-molecular-weight proteins that regulate cell trafficking by binding to specific G-protein-coupled seven-span transmembrane receptors on target cells. Chemokine receptors are classified by the type of chemokines they bind (CXC, CC, XC, CX3C), followed by R for receptor and a number indicating the order of discovery (2) . A number of chemokine receptors have ﹥1 known ligand and several chemokines are able to activate ﹥1 receptor. Thus, there is significant promiscuity in chemokine/receptor signaling.
The chemokine CXCL12/SDF-1 regulates a number of essential biological processes, including cardiac and neuronal development, stem cell motility, neovascularization, angiogenesis and apoptosis. In particular, CXCL12/SDF-1 promotes primary tumor growth and progression to metastasis. These processes are mediated by SDF-1 via its canonical receptor, known as CXCR4 (4) .
However, the metastatic behavior of carcinomas was only partially blocked by CXCR4 inhibition in vivo, suggesting that other genes may be involved in CXCL12/SDF-1-mediated tumorigenesis (3). An alternate receptor, the G-protein-coupled receptor CXCR7 (formerly known as RDC1) was recently shown to bind with high affinity to CXCL12/SDF-1 and CXCL11/I-TAC. Membrane-associated CXCR7 is expressed on a number of tumor cell lines, activated endothelial cells and fetal liver cells, but is absent on other cell types (4) . A receptor exhibited a four-fold higher expression in malignant pheochromocytomas compared with benign ones (5) . Ectopic CXCR7 expression in NIH 3T3 cells significantly increased cell proliferation and formed tumors when xenografted in nude mice (10) . CXCR7 overexpression provided tumor cells with increased adhesive and invasive properties, in addition to a growth and survival advantage in vivo. By contrast, CXCR7 downregulation using RNA interference exerted opposite effects. Specifically, RNAi-mediated CXCR7 downregulation inhibited tumor cell adhesion and invasion, thus conferring growth and survival disadvantages in vivo (1,3) . Xue et al (8) demonstrated that CXCR7 enhances the risk of extrahepatic metastasis in relatively well-differentiated hepatocellular carcinomas, potentially functioned by upregulation of osteopontin.
Several studies reported that CXCR7 regulates tumor development in vivo. Specifically, CXCR7 was shown to enhance tumor formation from breast, lung and prostate cancer cells (1, 3) and promoted experimental lung metastases from breast and osteosarcoma in mouse models (1, 11) . Furthermore, several human malignancies, including breast, lung, cervical, prostate, renal and esophageal tumors, pancreatic adenocarcinoma, Kaposi's sarcoma and cutaneous squamous cell carcinoma, were found to express elevated CXCR7 levels compared with normal tissues (1,3,10,12,13) . Additionally, in the majority of human cancers, the CXCR7 expression levels increased as the tumors became more aggressive.
Despite this evidence, a CXCR7 pathogenic mechanism has not been clearly determined. CD44 and cadherin-11 are among the potential downstream targets of CXCR7, which likely contribute to tumor cell invasiveness. CXCR7 also regulates the expression of the pro-angiogenic factors interleukin-8 or vascular endothelial growth factor (3). It was recently suggested that the biological effect of proliferation was attenuated and cell cycle arrest was caused by CXCR7 silencing in MCF-7 human breast cancer cells. Furthermore, CXCR7 knockdown attenuated the levels of phosphorylated epithelial growth factor receptor (EGFR) at tyrosine 1110 following EGF-stimulation and also decreased the phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in MCF-7 cells (9). Liu et al (14) observed that CXCR7 knockdown by siRNA decreased the phosphorylation of ERK1/2 and attenuated cell proliferation, invasion and migration in multiple glioblastoma multiforme cell lines. Therefore, we hypothesize that CXCR7 is involved in colon cancer development and lymph node metastasis.
The aim of the present study was to demonstrate that upregulated CXCR7 was correlated with human colon cancer. protein expression was found to be increased in colon tumors compared with that in normal colon tissues. In addition, the CXCR7 protein was increased in colon tumors with lymph node metastases (LN-) compared with the non-metastatic group (LN+). No significant difference was observed between well-differentiated adenocarcinomas (Well) and moderately-to-poorly differentiated adenocarcinomas (M-P).
Our data indicated that the CXCR7 transcript level was significantly elevated in colon cancer compared with normal colon tissue using a combination of mRNA and protein detection, and suggest that elevated CXCR7 expression promotes colon carcinogenesis. Additionally, as CXCR7 was found to be expressed, although at lower levels, in normal colon tissues, it is likely involved in non-malignant processes within the human colon.
Our results unequivocally demonstrated that CXCR7 was significantly upregulated in colon tumors with lymph node metastasis compared with non-metastatic colon tumors. These results are consistent with previous findings in prostate cancer (3) . Lymph node status was a significant risk factor predicting cancer recurrence (15) . Our study suggests that CXCR7 may be an important predictor of lymph node metastasis in colon cancer, but does not account for histopathological differences among colon cancer types. The sample size of the present study may not be optimal, but should be sufficient to draw a conclusion that may guide clinical decision-making.
